International Clinical Trial: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07513376) titled 'A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: Merck Sharp & Dohme LLC

Condition: Non-small Cell Lung Cancer

Intervention: Biological: Intismeran Biological: Pembrolizumab coformulated with berahyaluronidase alfa

Recruitment Status: Not recruiting...